Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.80 |
| ▸ | HTR2C | P28335 | 4/20 | 0.80 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 4/20 | 0.64 |
| ▸ | HTR2B | P41595 | 3/20 | 0.64 |
| ▸ | HTR1D | P28221 | 2/20 | 0.64 |
| ▸ | HTR1B | P28222 | 2/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | HTR1E | P28566 | 1/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.64 |
| ▸ | HTR7 | P34969 | 1/20 | 0.64 |
| ▸ | HTR6 | P50406 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28069265 | 1.00 | HTR2A (0.80) | HTR2AHTR2CGPR84HTR1AHTR2B | |
| SCHEMBL24178315 | 1.00 | HTR2A (0.80) | HTR2AHTR2CGPR84HTR1AHTR2B | |
| SCHEMBL29528195 | 1.00 | HTR2A (0.80) | HTR2AHTR2CGPR84HTR1AHTR2B | |
| SCHEMBL21292743 | 0.89 | HTR2A (1.00) | HTR2AHTR2CGPR84HTR1AHTR2B | |
| SCHEMBL19412024 | 0.89 | HTR2A (1.00) | HTR2AHTR2CGPR84HTR1AHTR2B | |
| SCHEMBL5555870 | 0.89 | HTR2A (1.00) | HTR2AHTR2CGPR84HTR1AHTR2B | |
| SCHEMBL3173954 | 0.89 | GPR84 (0.67) | HTR2AHTR2CGPR84HTR1AHTR2B | |
| Hydrochloric Acid SCHEMBL31143423 | 0.88 | HTR2A (0.97) | HTR2AHTR2CGPR84HTR1AHTR2B | |
| Hydrochloric Acid SCHEMBL20242634 | 0.88 | HTR2A (0.97) | HTR2AHTR2CGPR84HTR1AHTR2B | |
| SCHEMBL26996484 | 0.86 | HTR2A (0.79) | HTR2AHTR2CGPR84HTR1AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12303564-B2 | Composite chitosan-tannin-active agent compositions and methods of making and using same | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-05-20 | — | — | US | disclosed |
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| EP-4371977-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-05-22 | — | — | EP | disclosed |
| US-20230346811-A1 | Novel Formulations of Psilocybin And Psilocin Compounds as Serotonin Agonists in Combination With 3,4 Methylenedioxymethamphetamine (MDMA) | Altrartis Therapeutics Inc. | 2023-11-02 | — | — | US | disclosed |
| US-20230257347-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257347-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257347-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20220296720-A1 | COMPOSITE CHITOSAN-TANNIN-ACTIVE AGENT COMPOSITIONS AND METHODS OF MAKING AND USING SAME | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2022-09-22 | — | — | US | disclosed |
| CN-109415361-B | Acrylic acid derivative, preparation method thereof and application thereof in medicine | 浙江海正药业股份有限公司 | 2022-03-08 | — | — | CN | disclosed |
| WO-2021055749-A1 | THERAPEUTIC CONJUGATES | TOTUS MEDICINES INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| WO-2005056554-A2 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| EP-1539141-A1 | -3 (SULFONAMIDOETHYL) -INDOLE DERIVATIES FOR USE AS GLUCOCORTICOID MIMETICS IN THE TREATMENT OF INFLAMMATORY, ALLERGIC AND PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1532153-A1 | AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X-Ceptor Therapeutics, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20050054634-A1 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | AKARNA THERAPEUTICS, LTD. (GB) | 2005-03-10 | — | — | US | disclosed |
| US-20040097574-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-05-20 | — | — | US | disclosed |
| WO-2004019935-A1 | -3 (SULFONAMIDOETHYL) -INDOLE DERIVATIES FOR USE AS GLUCOCORTICOID MIMETICS IN THE TREATMENT OF INFLAMMATORY, ALLERGIC AND PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| US-20040023947-A1 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | X-CEPTOR THERAPEUTICS INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003099821-A1 | AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| US-5436264-A | Adrenergic blocking agents for vasoconstriction and hypotensive agents | SYNTEX (U.S.A.) INC. (US) | 1995-07-25 | — | — | US | disclosed |
| US-5405866-A | Administering with cytostatic drugs to treat drug resistant tumors | HOFFMANN-LA ROCHE INC. (US) | 1995-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | GPER1, ESR1, ESRRA | HTR2A 421/4885HTR2C 316/4885GPR84 259/4885 |
| US-20040023947-A1 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | HTR5A, MTNR1A, PTGDR | HTR2A 10/4885HTR2C 6/4885GPR84 246/4885 |
| US-20220296720-A1 | COMPOSITE CHITOSAN-TANNIN-ACTIVE AGENT COMPOSITIONS AND METHODS OF MAKING AND USING SAME | TTPA, CHIA, CHIT1 | HTR2A 2918/4885HTR2C 3495/4885GPR84 4435/4885 |
| US-20040097574-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | HTR2A 1707/4885HTR2C 1221/4885GPR84 271/4885 |
| US-12303564-B2 | Composite chitosan-tannin-active agent compositions and methods of making and using same | TTPA, CHIA, CHIT1 | HTR2A 2918/4885HTR2C 3495/4885GPR84 4435/4885 |
| US-20230257347-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | HTR6, TPH2, TPH1 | HTR2A 13/4885HTR2C 23/4885GPR84 984/4885 |
| US-20050054634-A1 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | GPR119, IRS1, INSR | HTR2A 309/4885HTR2C 974/4885GPR84 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.